메뉴바로가기
메인메뉴 바로가기
컨텐츠 바로가기

메인비쥬얼

Group Introduction

메인 컨텐츠

News

Title Huons Meditech Participates in MEDICA 2025 in Germany
User PR Date 2025-11-20
Attachment

 

Huons Meditech Participates in MEDICA 2025 in Germany

- CE-MDR certified Dermashine line draws strong attention -

- “Strengthening global presence and expanding new partnerships” -


보도사진_휴온스메디텍, 독일 국제의료기기전시회 `MEDICA 2025` 참가.JPG

(Photo Description) Huons Meditech recently participated in ‘MEDICA 2025,’ the international medical device exhibition held in Düsseldorf, Germany. On the photo, a representative of Huons Meditech is presenting ‘Dermashine’ series to the exhibition participants.

 

Huons Meditech, a medical device subsidiary of Huons Group, showcased its flagship products, including the ‘Dermashine’ series, at one of the world’s leading medical exhibitions.

Huons Meditech (CEO Changwoo Ha) announced on the 20th that it took part in ‘MEDICA 2025,’ held in Düsseldorf, Germany, from November 17.

MEDICA’ is one of the world’s largest medical device exhibitions, with more than 5,000 companies from over 70 countries participating annually. It is widely recognized as a key global platform to explore the latest technologies and innovations in the medical device sector.

At this year’s exhibition, Huons Meditech strengthened its global network across Europe, the Middle East, and Asia, while actively promoting its products and brand in the medical and aesthetic device markets.

During MEDICA 2025, the company highlighted the excellence of various medical devices, including its Dermashine product lineup (Dermashine Pro and Dermashine Balance). Dermashine is a globally proven aesthetic medical device brand with over 20,000 units sold worldwide, featuring highly precise drug delivery technology and a user-friendly interface. In August, the Dermashine series became the first electrically powered drug delivery device developed by a Korean company to receive CE-MDR certification (Medical Device Regulation). Since then, the company has actively promoted its performance through campaigns emphasizing the importance of using genuine needles.

The extracorporeal shockwave lithotriptor ‘URO-UEMXD,’ which combines a shockwave head and ultrasound in an in-line structure, also attracted significant attention. The URO-UEMXD is the first Korean-made device to combine these two components in a straight in-line configuration, overcoming the limitations of conventional X-ray–based stone localization systems. Huons Meditech also showcased additional products including the endoscope reprocessor ‘HUEN DR-02,’ further highlighting the breadth of its medical device portfolio.

CEO Changwoo Ha stated, “Our participation in MEDICA 2025 has strengthened our presence in the European market and created new opportunities for global collaboration. We will continue to enhance our competitiveness in the global medical device industry through ongoing technological innovation and quality advancement.”

Huons Meditech continues to lay the groundwork for European market expansion through CE-MDR certification and is actively pursuing new partnerships not only in Europe but also across the Middle East and Asia by promoting its technological excellence and product competitiveness.

 

목록
Total 92, 1/10 Page
Number Title Date Read
92 Huons Global Reports FY2025 Results, Revenue of KRW 847.5 Billion.. 2026-02-13 89
91 Huonslab on Track for Recombinant Human Hyaluronidase ‘HYDIZYME.. 2026-02-11 116
90 Huons Meditech Showcases at ‘WHX Dubai 2026’, Accelerating Ex.. 2026-02-10 102
89 PanGen Biotech Announces FY2025 Results, Revenue of KRW 13.42 Bil.. 2026-02-03 151
88 Huons Signs Distribution Agreement with Rappeler for Vitamin C an.. 2026-01-30 203
87 Humedix Celebrated a Symposium to Mark the Launch of Three Types .. 2026-01-22 346
86 Humedix Announces Syrian Approval for Three Types of HA Filler .. 2026-01-12 379
85 Huons BioPharma Secures NMPA Approval for Type A Botulinum Toxin .. 2026-01-09 537
84 Huons Group Kicks Off New Year with Employees, “New Beginning f.. 2026-01-06 358
83 Huonslab has submitted the Biologics License Application for Reco.. 2025-12-22 731

1 2 3 4 5 6 7 8 9 10